Reconfirmation of Market Guidance and AGM Q&A

AI SummaryClose X

SkinBioTherapeutics plc has confirmed that its trading for the new financial year has started positively and anticipates reporting full-year 2026 results in line with market expectations, which include revenue of £6.2 million and adjusted EBITDA of £0.7 million. The company also provided a Q&A for shareholders regarding the upcoming Annual General Meeting.

Disclaimer*

UK 100

Latest directors dealings